TG Therapeutics saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 94 the day before.
Lean How — And When — To Sell Stocks
The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that's an important benchmark to look for when looking for the best stocks to buy and watch.
TG Therapeutics broke out earlier, but has fallen back below the prior 36.84 entry from a consolidation. If a stock you're tracking breaks past a buy point then falls 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new base and breakout.
The stock has an 80 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of D shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
In Q1, the company posted 0% earnings-per-share growth. Sales growth came in at 90%, down from 146% in the previous quarter.
TG Therapeutics holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
